Illumina, the world’s largest gene sequencing company, faces a record fine from the E.U. for acquiring startup Grail without approval. The $8 billion deal closed in August 2021 despite ongoing EU. and U.S. investigations. A year later, the EU prohibited the merger, citing reduced innovation and choice. The expected $453 million fine, which would be…

The Supreme Court’s recent decision in the case of Amgen Inc. v. Sanofi (No. 21-757) could chart a new course for both the pharmaceutical industry and patent law. In this decision, the Supreme Court provided clarity on what the Patent Act means by ‘enablement,’ raising the bar for the level of detail needed in certain…